Statistics of MONALEESA-3 : A phase III study of Ribociclib (LEE011) with Fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in postmenopausal women who have received no or only one line of prior endocrine therapy